Valneva SE (XPAR:VLA) FCF Margin % : -100.64% (As of Mar. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Valneva SE FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Valneva SE's Free Cash Flow for the three months ended in Mar. 2024 was €-33.0 Mil. Valneva SE's Revenue for the three months ended in Mar. 2024 was €32.8 Mil. Therefore, Valneva SE's FCF Margin % for the quarter that ended in Mar. 2024 was -100.64%.

As of today, Valneva SE's current FCF Yield % is -40.36%.

The historical rank and industry rank for Valneva SE's FCF Margin % or its related term are showing as below:

XPAR:VLA' s FCF Margin % Range Over the Past 10 Years
Min: -145.04 Med: -4.46 Max: 107.2
Current: -145.04

During the past 13 years, the highest FCF Margin % of Valneva SE was 107.20%. The lowest was -145.04%. And the median was -4.46%.

XPAR:VLA's FCF Margin % is ranked worse than
50.24% of 1047 companies
in the Biotechnology industry
Industry Median: -143.92 vs XPAR:VLA: -145.04

Valneva SE FCF Margin % Historical Data

The historical data trend for Valneva SE's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Valneva SE FCF Margin % Chart

Valneva SE Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-4.24

107.20

-4.67

-76.02

-141.21

Valneva SE Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Margin %	Get a 7-Day Free Trial															-84.08	-110.44	-190.74	-171.44	-100.64

Competitive Comparison of Valneva SE's FCF Margin %

For the Biotechnology subindustry, Valneva SE's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Valneva SE's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Valneva SE's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Valneva SE's FCF Margin % falls into.

Valneva SE FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Valneva SE's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-217.056	/	153.712
	=	-141.21 %

Valneva SE's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-32.964	/	32.753
	=	-100.64 %

Valneva SE FCF Margin % Related Terms

Thank you for viewing the detailed overview of Valneva SE's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Valneva SE (XPAR:VLA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Valneva SE (XPAR:VLA) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

VALN:USA INRLF:USA AYJ:Germany VLA:Austria

Address

6 Rue Alain Bombard, Saint-Herblain, FRA, 44800

Website

https://www.valneva.com

Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes two vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, & third-party products; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The majority is from the Commercialized vaccines segment & geographically from the United States.

Valneva SE (XPAR:VLA) Headlines

No Headlines